Topical Tacrolimus Progylcosomes Nano-Vesicles As a Potential Therapy for Experimental Dry Eye Syndrome.

Abstract

The present work aimed to evaluate the efficacy of topical tacrolimus (0.01%) loaded propylene glycol (PG) modified nano-vesicles (Proglycosomes Nano-vesicles, PNVs) for the treatment of experimental dry eye syndrome (DES) in rabbits. DES was induced by topical application of atropine (1.0%) and benzalkonium chloride (0.1%) aqueous solution. PNVs treatment (PNV group) was compared with tacrolimus solution 0.01% (TAC group) and untreated group and healthy group were used as controls. PNV treated animals showed improved clinical performance with marked increase in tear production and tear break-up time (TBUT). Further, PNVs also subside ocular inflammation as evident from absence of matrix metalloprotenaise-9 and normal ocular surface temperature (32.3 ± 0.34 °C). Additionally, PNVs have positive effect on ocular and epithelial damage observed through low ocular surface staining score and improved globlet cell density. The PNV treatment was found to more effectively compared to TAC solution and most of the parameters were close to those of healthy animals. In conclusion, tacrolimus PNV formulation (0.01%) could be a potential therapy for treatment of dry eye syndrome.

• Authors: Mohammad, Vaidehi Garg, Jayabalan Nirmal, Musarrat H Warsi, Deepti Pandita, Prashant Kesharwani, Gaurav Kumar Jain
• Journal: Journal of pharmaceutical sciences (J Pharm Sci) Vol. 111 Issue 2 Pg. 479-484 (02 2022) ISSN: 1520-6017 [Electronic] United States
• PMID: 34599998 (Publication Type: Journal Article)
• Copyright: Copyright © 2021 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.

Chemical References

• Propylene Glycol
• Tacrolimus

Topics

• Animals
• Dry Eye Syndromes (drug therapy)
• Inflammation
• Propylene Glycol
• Rabbits
• Tacrolimus
• Tears